Izrael - angielski - Ministry of Health

medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.

Izrael - angielski - Ministry of Health

medison pharma ltd - nusinersen - solution for injection - nusinersen 2.4 mg / 1 ml - spinraza is indicated for the treatment of 5q spinal muscular atrophy except type 0 and type iv.

Arabia Saudyjska - angielski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

biogen idec ltd, united kingdom - nusinersen - solution for injection - 12 mg

Arabia Saudyjska - angielski - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

biogen idec b.v-natherland, netherlands - nusinersen - solution for injection - 12 mg

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - risdiplam 0.75 mg/ml - powder for oral solution - 750 mcg/ml - active: risdiplam 0.75 mg/ml excipient: ascorbic acid disodium edetate dihydrate isomalt macrogol 600 mannitol sodium benzoate strawberry flavour phs-180152 sucralose tartaric acid - evrysdi is indicated for the treatment of spinal muscular atrophy (sma) in patients aged 2 months and older.

Unia Europejska - angielski - EMA (European Medicines Agency)

roche registration gmbh  - risdiplam - muscular atrophy, spinal - other drugs for disorders of the musculo-skeletal system - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies. 

Kanada - angielski - Health Canada

hoffmann-la roche limited - risdiplam - powder for solution - 0.75mg - risdiplam 0.75mg - other miscellaneous therapeutic agents

Singapur - angielski - HSA (Health Sciences Authority)

roche singapore pte. ltd. - risdiplam - powder, for solution - risdiplam 60 mg

Izrael - angielski - Ministry of Health

roche pharmaceuticals (israel) ltd - risdiplam - powder for solution - risdiplam 60 mg/bottle - risdiplam - evrysdi is indicated for the treatment of spinal muscular atrophy (sma) types 1,2 and 3 in patients 2 months of age and older.